Optiver Holding
TVTX icon

Optiver Holding’s Travere Therapeutics TVTX Stock Holding History

Optiver Holding’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33K Sell
41
-213
-84% -$9.44K ﹤0.01% 2265
2026
Q1 		$7.55K Buy
254
+131
+107% +$3.92K ﹤0.01% 1295
2025
Q4 		$4.7K Sell
123
-435
-78% -$14.1K ﹤0.01% 1412
2025
Q3 		$13.3K Buy
558
+8
+1% +$150 ﹤0.01% 1126
2025
Q2 		$8.14K Buy
550
+146
+36% +$2.42K ﹤0.01% 1058
2025
Q1 		$7.24K Buy
+404
New +$8.2K ﹤0.01% 993

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's TVTX Position: Q2 2026 in Review

Optiver Holding reduced its Travere Therapeutics (TVTX) stake by 84% in Q2 2026, selling an estimated $9.44K and leaving 41 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Optiver Holding first reported a position in TVTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $13.3K in Q3 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Optiver Holding held 41 shares of Travere Therapeutics worth $2.33K as of Q2 2026.
  • Optiver Holding sold 213 Travere Therapeutics shares in Q2 2026, an estimated $9.44K.
  • Travere Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2265 holding.
  • Optiver Holding first reported a position in Travere Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Optiver Holding's Travere Therapeutics position peaked at $13.3K in Q3 2025.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.